China SXT Pharmaceuticals (SXTC) Finished Goods (2021 - 2026)

China SXT Pharmaceuticals has reported Finished Goods for 6 years, with the latest figure at $639602.0 in Q1 2026.

• On a quarterly basis, Finished Goods rose 42.56% year-over-year to $639602.0 in Q1 2026; TTM through Mar 2026 was $639602.0, a 42.56% increase from a year earlier, with the FY2026 full-year figure at $639602.0, up 42.56% from the prior year.
• Finished Goods was $639602.0 for Q1 2026 at China SXT Pharmaceuticals, up from $511307.0 in the prior quarter.
• The five-year high for Finished Goods was $639602.0 in Q1 2026, with the low at $446866.0 in Q1 2023.
• Average Finished Goods over 5 years is $546743.8, with a median of $569214.5 recorded in 2022.
• The sharpest annual moves came in 2023 and 2026: Finished Goods slipped 23.58% in 2023, then soared 42.56% in 2026.
• Over 5 years, Finished Goods stood at $588827.0 in 2022, then decreased by 24.11% to $446866.0 in 2023, then soared by 34.32% to $600251.0 in 2024, then declined by 14.82% to $511307.0 in 2025, then rose by 25.09% to $639602.0 in 2026.
• The last three Finished Goods figures came in at $639602.0 (Q1 2026), $511307.0 (Q3 2025), and $448668.0 (Q1 2025), per Business Quant data.